Last reviewed · How we verify
Intensified chemotherapy
Intensified chemotherapy uses higher doses or more aggressive combinations of cytotoxic agents to maximize tumor cell kill in sarcoma patients.
Intensified chemotherapy uses higher doses or more aggressive combinations of cytotoxic agents to maximize tumor cell kill in sarcoma patients. Used for High-risk or metastatic soft tissue sarcoma, Osteosarcoma.
At a glance
| Generic name | Intensified chemotherapy |
|---|---|
| Also known as | Vincristine,, Doxorubicin, Ifosfamide, Cyclophosphamide, Etoposide |
| Sponsor | Italian Sarcoma Group |
| Drug class | Cytotoxic chemotherapy combination |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach involves escalating standard chemotherapy regimens—typically multi-agent combinations such as doxorubicin, cisplatin, and ifosfamide—to achieve greater cytotoxic effect against sarcoma cells. The intensification strategy aims to improve disease control and survival outcomes, particularly in high-risk or advanced sarcoma cases, by pushing tolerability limits while managing supportive care.
Approved indications
- High-risk or metastatic soft tissue sarcoma
- Osteosarcoma
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Cardiotoxicity (doxorubicin-related)
- Nephrotoxicity (cisplatin-related)
- Ototoxicity
- Alopecia
Key clinical trials
- A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events (NA)
- De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (PHASE2, PHASE3)
- Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma (PHASE2)
- Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma (NA)
- Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer (PHASE2)
- Intensified Chemotherapy in CRC After Resection of Liver Metastases (PHASE2, PHASE3)
- Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma (PHASE3)
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensified chemotherapy CI brief — competitive landscape report
- Intensified chemotherapy updates RSS · CI watch RSS
- Italian Sarcoma Group portfolio CI